Table 3 |
|||||
| Variance in preoperative clinicopathological parameters between patients with and without positive surgical margin (PSM) | |||||
|
PSM present (n = 39) |
PSM absent (n = 81) |
Uniivariate | Multivariate | ||
| p-value | P value | Adjusted odds ratio (95% CI) | |||
| Mean age [years] | 63.5 ± 36.0 | 64.0 ± 4.6 | 0.993 | ||
| PSA [ng/ml] | 9.8 ± 6.3 | 8.7 ± 7.8 | 0.247 | ||
| Gleason score at biopsy | 7.2 ± 1.2 | 7.0 ± 1.0 | 0.209 | ||
| cT stage (n) | 0.347 | ||||
| T1c | 30 (76.9%) | 65 (80.2%) | |||
| T2 | 5 (12.8%) | 13 (16.0%) | |||
| T3a | 4 (10.3%) | 3 (3.7%) | |||
| %positive cores | 31.0 ± 21.3 | 21.3 ±16.4 | 0.001 | 0.001 | 1.044 (1.019-1.070) |
| TZ biopsy positive (n) | 17 (43.6%) | 24 (29.6%) | 0.131 | ||
| Number of apex-positive (2–4/0–1) (n) | 14/25 | 15/66 | 0.037 | ||
| Number of middle-positive (2–4/0–1) (n) | 17/22 | 15/66 | 0.004 | ||
| Number of base-positive (2–4/0–1) (n) | 13/26 | 14/67 | 0.049 | ||
PSA, prostate-specific antigen; TZ, transition zone; apex, prostatic apex biopsy; middle, prostatic middle biopsy; base, prostatic base biopsy. Data not available in 4 patients.
Ishizaki et al. Diagnostic Pathology 2012 7:68 doi:10.1186/1746-1596-7-68
